

## **PRESS RELEASE**

### **Heidelberg Pharma Receives Milestone Payment from Partner Magenta**

**Ladenburg, Germany, 14 September 2020** – Heidelberg Pharma AG (FSE: HPHA) announced today that it has received a milestone payment from its cooperation partner Magenta Therapeutics, Cambridge, MA, USA, (Magenta) (NASDAQ: MGTA) associated with the initiation of the GLP toxicology study for the development candidate MGTA-117.

Prof. Andreas Pahl, CSO of Heidelberg Pharma AG, commented: "We are delighted that Magenta is advancing the program forward toward clinical trials for MGTA-117. MGTA-117, an antibody amanitin conjugate based on our ATAC technology, is intended to be developed for the targeted conditioning of patients undergoing stem cell transplants due to blood cancer or genetic diseases."

#### **About Magenta Therapeutics**

Headquartered in Cambridge, Mass., Magenta Therapeutics is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune diseases, blood cancers and genetic diseases. By creating a platform focused on critical areas of unmet need, Magenta Therapeutics is pioneering an integrated approach to allow more patients to receive one-time, curative immune reset.

#### **About Heidelberg Pharma's proprietary ATAC technology**

Antibody drug conjugates (ADCs) combine the high affinity and specificity of antibodies with the potency of cytotoxic small molecules for the treatment of cancer. Antibody Targeted Amanitin Conjugates (ATACs) are ADCs whose active ingredient is made up of amatoxin molecules. Amatoxins are small bicyclic peptides naturally occurring in the death cap mushroom. They inhibit mRNA transcription by binding to RNA polymerase II, a mechanism that is crucial for the survival of eukaryotic cells. In preclinical testing, ATACs have been shown to be highly efficacious, overcoming frequently encountered resistance mechanisms and combating even quiescent tumor cells.

#### **About Heidelberg Pharma**

Heidelberg Pharma AG is a biopharmaceutical company based in Ladenburg, Germany. Heidelberg Pharma is an oncology specialist and the first company to develop the toxin Amanitin into cancer therapies. The proprietary technology platform is being applied to develop the Company's proprietary therapeutic ATACs as well as in third-party collaborations. The proprietary lead candidate HDP-101 is a BCMA ATAC for multiple myeloma. Heidelberg Pharma AG is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol HPHA. More information is available at [www.heidelberg-pharma.com](http://www.heidelberg-pharma.com).

**Contact**

Heidelberg Pharma AG  
Sylvia Wimmer  
Tel.: +49 89 41 31 38-29  
Email: investors[at]hdpharma.com  
Gregor-Mendel-Str. 22, 68526 Ladenburg

**IR/PR support**

MC Services AG  
Katja Arnold (CIRO)  
Managing Director & Partner  
Tel.: +49 89 210 228-40  
Email: katja.arnold[at]mc-services.eu

This communication contains certain forward-looking statements relating to the Company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "will" "should" "future", "potential" or similar expressions or by a general discussion of the Company's strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.